Australia's PainChek drops most in nearly 8 years on FDA approval delay

PainChek

05/06/2025 05:13

** PainChek PCK.AX plunges as much as ~31% to A$0.038; marks biggest intraday pct drop since June 18, 2017

** Stock hits lowest since May 7

** Medical devices maker flags potential delay in U.S. FDA clearance for its pain assessment app

** Expects clearance by mid-to-late September instead of the first half of 2025 anticipated earlier

** About 14.3 mln shares traded in stock's busiest day since February 18, 2021

** PCK last up 21.8%, taking YTD gains to 48.3%

 (Reporting by Keshav Singh Chundawat in Bengaluru)

 ((Keshav.SinghChundawat@thomsonreuters.com;))